BTIG Reiterates Buy on Mereo BioPharma Group, Maintains $1 Price Target

Benzinga · 1d ago
BTIG analyst Julian Harrison reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $1 price target.